A Phase 1 Study of ANJ900 Chinese Healthy Subjects
Status:
Active, not recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This will be a Phase 1, randomised, open label, 3 way crossover study in healthy male and
female Chinese subjects. Subjects will participate in 3 treatment periods and will be
randomised in a 1:1:1 ratio to 1 of 3 treatment sequences. There will be a washout period of
7 days between doses.